Epilepsy | Disease Landscape and Forecast | G7 | 2024
Epilepsy, which afflicts approximately 4.7 million people in the major markets according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment based largely on the patient’s seizure syndrome and seizure type. The market is heavily genericized, and most antiepileptic drugs (AEDs) can be used as monotherapy or in combination. The second-generation AEDs continue to dominate the market; however, recent entrants like cenobamate, fenfluramine, and ganaxolone are carving out market share, despite being high-priced branded products, by targeting underserved and orphan epilepsy populations. This report details the market potential of agents in late-phase development for orphan indications, such as soticlestat, lorcaserin, and carisbamate. It provides a detailed profile of novel—and potentially disease-modifying—therapies in earlier development (e.g., the gene therapies STK-001 [Stoke Therapeutics]).
Questions answered
- What is the size of the epilepsy market by country, and how will the market evolve in the coming decade?
- What key factors will shape the future market, and what drivers and barriers will influence using key AEDs? Which therapies will be commercially successful over the forecast period?
- How will high-priced third-generation AEDs fare in this highly genericized market?
- What are the unmet needs in the treatment of epilepsy? How will emerging therapies address these unmet needs?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: Approximately 20 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other Clarivate research.
Epidemiology: Diagnosed prevalence of epilepsy by country, segmented by generalized and partial-onset seizures; drug-treated cases.
Drug treatments: Coverage of key current and emerging therapies
Market forecast features: Patient-based market forecast extending through 2033, segmented by brands and generics/biosimilars.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
